Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
Public ClinicalTrials.gov record NCT00080262. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of Novel Epothilone (BMS-247550) in Patients With MBC Who Are Refractory to an Anthracycline, a Taxane, and Capecitabine
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.
Study identification
- NCT ID
- NCT00080262
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 125 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2004 (Type not available)
- Primary completion
- Dec 2006 (Actual)
- Completion
- Dec 2006 (Actual)
- Last update posted
- Jan 30, 2017
2004 – 2006
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | La Verne | California | — | — |
| Local Institution | Meriden | Connecticut | — | — |
| Local Institution | Jacksonville | Florida | — | — |
| Local Institution | Baltimore | Maryland | — | — |
| Local Institution | Boston | Massachusetts | — | — |
| Local Institution | New York | New York | — | — |
| Local Institution | Asheville | North Carolina | — | — |
| Local Institution | Charlotte | North Carolina | — | — |
| Local Institution | Pittsburgh | Pennsylvania | — | — |
| Local Institution | Providence | Rhode Island | — | — |
| Local Institution | Chattanooga | Tennessee | — | — |
| Local Institution | Jackson | Tennessee | — | — |
| Local Institution | Knoxville | Tennessee | — | — |
| Local Institution | Nashville | Tennessee | — | — |
| Local Institution | Houston | Texas | — | — |
| Local Institution | San Antonio | Texas | — | — |
| Local Institution | Salt Lake City | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00080262, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 30, 2017 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00080262 live on ClinicalTrials.gov.